SCHEMBL21165288

SCHEMBL21165288

O=C(CN1CC[C@@H](O)[C@@H](F)C1)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ CYP2C19 P33261 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ DPP4 P27487 2/20 0.40
▸ DPP7 Q9UHL4 2/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM5 P08912 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21100504 1.00 ALDH1A1 (0.43) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL21100502 1.00 ALDH1A1 (0.43) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL21100503 1.00 ALDH1A1 (0.43) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL19465293 0.85 SMN1; SMN2 (0.46) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL19841978 0.85 MEN1 (0.49) ALDH1A1MAPK1L3MBTL1SMN1; SMN2MEN1
SCHEMBL21100933 0.84 LTA4H (0.48) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL18909590 0.84 SMN1; SMN2 (0.48) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL23027037 0.83 LTA4H (0.48) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL22280532 0.83 LTA4H (0.48) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1
SCHEMBL16228724 0.81 NPC1 (0.53) ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11230556-B2 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor MERCK SHARP & DOHME CORP. (US) 2022-01-25 — — US disclosed
US-10351564-B2 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor Merck Sharop & Dohme, Corp. (US) 2019-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230556-B2 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor CHRM5, CHRM4, CHRM2 ALDH1A1 3051/4885MAPK1 4429/4885L3MBTL1 1643/4885
US-10351564-B2 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor CHRM5, CHRM4, CHRM1 ALDH1A1 2056/4885MAPK1 3776/4885L3MBTL1 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback